🇺🇸 FDA
Patent

US 9163085

Anti-OX40 antibodies and methods of treating cancer

granted A61KA61K2039/505A61P

Quick answer

US patent 9163085 (Anti-OX40 antibodies and methods of treating cancer) held by The Board of Regents of the University of Texas System expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/505, A61P, A61P35/00, A61P37/00